Kullich W, Fromme K, Klein G
Ludwig-Boltzmann-Institut für Rehabilitation interner Erkrankungen, Saalfelden.
Wien Med Wochenschr. 1996;146(17):459-64.
Most undesired side effects in therapy with non-steroidal antiinflammatory drugs (NSAID) mainly effect the gastric and duodenal mucosa. The radioimmunological determination of pepsinogen A and C (pepsinogen group I and II) is qualified for inclusion of the functional and morphologic state of the gastroduodenal mucosa. By determination of the pepsinogens group A and C the influence and the gastroduodenal compatibility of the non-steroidal antiinflammatory drug lonazolac Ca (LCa) [Irritren] were examined in a dosage of 600 mg/d during a 2-weeks therapy. 31 patients with various painful rheumatic diseases and 10 healthy probands as a control group were examined. The results show that the treatment with LCa did not significantly effect mean and median of pepsinogen A- and -C levels in serum. Only in 3.7% of the cases a contemporary increase of pepsinogen A and C occurred, which could be estimated as a beginning superficial gastritis. In addition the beneficial clinical efficacy of LCa was documented by a significant decrease of a tripartite pain score from 2.1 to 1.4. The results point to a very good proportion of clinical efficacy and gastroduodenal side-effects of LCa.
非甾体抗炎药（NSAID）治疗中多数不良副作用主要影响胃和十二指肠黏膜。胃蛋白酶原A和C（胃蛋白酶原I组和II组）的放射免疫测定适用于评估胃十二指肠黏膜的功能和形态状态。通过测定胃蛋白酶原A组和C组，研究了非甾体抗炎药氯那唑酸钙（LCa）[伊瑞特林]在600 mg/d剂量下进行为期2周治疗时对胃十二指肠的影响及其与胃十二指肠的相容性。研究了31例患有各种疼痛性风湿疾病的患者以及10名健康受试者作为对照组。结果表明，LCa治疗对血清中胃蛋白酶原A和C水平的均值和中位数无显著影响。仅在3.7%的病例中出现胃蛋白酶原A和C同时升高的情况，这可被视为浅表性胃炎的初期表现。此外，LCa的有益临床疗效通过三方疼痛评分从2.1显著降至1.4得到证实。结果表明LCa在临床疗效和胃十二指肠副作用方面具有很好的比例关系。
